Safety, Pharmacokinetics, and Pharmacodynamics of Drotrecogin Alfa (Activated) in Children with Severe Sepsis

Pediatrics

Volumn 113, Issue 1 I, 2004, Pages 7-17

  Barton, Phil ^a   Kalil, Andre C ^b,m   Nadel, Simon ^c   Goldstein, Brahm ^d   Okhuysen Cawley, Regina ^e   Brilli, Richard J ^f   Takano, Jeanne S ^g   Martin, Lynn D ^h   Quint, Peter ⁱ   Yeh, Timothy S ^j,n   Dalton, Heidi J ^k   Gessouron, Morris R ^l   Brown, Kellie E ^a   Betts, Helen ^c   Levin, Michael ^c   Macias, William L ^b   Small, David S ^b   Wyss, Virginia L ^b   Bates, Becky M ^b   Utterback, Barbara G ^b   Giroir, Brett P ^g,o   more..

^a Children's Hospital at Saint Francis   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c ST MARY S HOSPITAL   (United Kingdom)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

ⁱ Legacy Emmanuel Hospital   (United States)

^j CHILDREN S HOSPITAL OAKLAND   (United States)

^k CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^l Children's Hospital Oklahoma City   (United States)

^m UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁿ CHILDREN S HOSPITAL OF NEW JERSEY   (United States)

^o CHILDREN S MEDICAL CENTER   (United States)

more..

Author keywords

Activated protein C; Drotrecogin alfa (activated); Pediatric; Sepsis; Xigris

Indexed keywords

ANTITHROMBIN; D DIMER; DROTRECOGIN; PLACEBO; PROTEIN C;

ADOLESCENT; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANDIDA; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD MORTALITY; CHOREOATHETOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; EDEMA; FEMALE; FEVER; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HERPES SIMPLEX VIRUS; HUMAN; INFANT; INFECTION; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTITHROMBINS; CHILD; CHILD, PRESCHOOL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROTEIN C; PROTEIN C DEFICIENCY; RECOMBINANT PROTEINS; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 9144264948     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.113.1.7     Document Type: Article

References (34)

1. Hazelzet JA, Risseeuw-Appel IM, Kornelisse RF, et al. Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb Haemost. 1996;76:932-938
2. Anderson MR, Blumer JL. Advances in the therapy for sepsis in children. Pediatr Clin North Am. 1997;44:179-205
3. Martinot A, Leclerc F, Cremer R, Leteurtre S, Fourier C, Hue V. Sepsis in neonates and children: definitions, epidemiology, and outcome. Pediatr Emerg Care. 1997;13:277-281
4. Beutler B, Poltorak A. Sepsis and evolution of the innate immune response. Crit Care Med. 2001;29(7 suppl):S2-S6
5. Ulevitch RJ. New therapeutic targets revealed through investigations of innate immunity. Crit Care Med. 2001;29(7 suppl):S8-S12
6. Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit Care Med. 2001;29(7 suppl):S21-S27
7. Aird WC. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med. 2001;29(7 suppl):S28-S34
8. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276:11199-11203
9. Butt W. Septic shock. Pediatr Clin North Am. 2001;48:601-625
10. Marlar RA, Kleiss AJ, Griffin JH. Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. Ann N Y Acad Sci. 1981;370:303-310
11. Gruber A, Hanson SR, Kelly AB, et al. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation. 1990;82:578-585
12. van Hinsbergh VW, Bertina RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood. 1985;65:444-451
13. de Fouw NJ, van Tilburg NH, Haverkate F, Bertina RM. Activated protein C accelerates clot lysis by virtue of its anticoagulant activity. Blood Coagul Fibrinolysis. 1993;4:201-210
14. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem. 1996;271:22949-22952
15. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol. 2000;20:2511-2518
16. Esmon CT. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway. J Autoimmun. 2000;15:113-116
17. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol. 1994;153:3664-3672
18. Hancock WW, Grey ST, Hau L, et al. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation. 1995;60:1525-1532
19. Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol. 1997;272(pt 1):L197-L202
20. Grinnell BW, Hermann RB, Yan SB. Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology. 1994;4:221-225
21. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med. 2001;29(7 suppl):S48-S51
22. Fijnvandraat K, Derkx B, Peters M, et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost. 1995;73:15-20
23. Krafte-Jacobs B, Brilli R. Increased circulating thrombomodulin in children with septic shock. Crit Care Med. 1998;26:933-938
24. Faust SN, Heyderman RS, Levin M. Coagulation in severe sepsis: A central role for thrombomodulin and activated protein C. Crit Care Med. 2001;29:S62-S68
25. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709
26. US Department of Health and Human Services. General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products, Draft Guidance. Rockville, MD: Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), US Department of Health and Human Services, Food and Drug Administration; 1998
27. Food and Drug Administration. Draft Guidance E11: Clinical Investigation of Medicinal Products in the Pediatric Population. Rockville, MD: Federal Register; April 12, 2000. 65:19777-19781. Docket No. 00D-1223
28. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE, Russel JA. Safety and dose relationship of recombinant human activated protein C (rhAPC) on coagulopathy in severe sepsis. Crit Care Med. 2001;29:2051-2059
29. Wilkinson JD, Pollack MM, Glass NL, Kanter RK, Katz RW, Steinhart CM. Mortality associated with multiple organ system failure and sepsis in pediatric intensive care unit. J Pediatr. 1987;111:324-328
30. Shann F, Pearson G, Slater A, Wilkinson K. Paediatric index of mortality (PIM): a mortality prediction model for children in intensive care. Intensive Care Med. 1997;23:201-207
31. Macias WL, Dhainaut JF, Yan SC, et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) (recombinant human activated protein C) in patients with severe sepsis. Clin Pharmacol Ther. 2002;72:391-402
32. Vincent JL, Ely EW, Bernard GR. Mortality reduction associated with recombinant human activated protein C [drotrecogin alfa (activated)] in patients with severe sepsis as assessed by markers of disease severity. Paper presented at: 14th Annual Conference of European Society of Intensive Care Medicine; September 30, 2001; Geneva, Switzerland
33. Vincent JL, Angus DC, Artigas A. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003;31: 834-840
34. Olson RE. Nutrition: general considerations. In: Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck & Co Inc; 1999. Available at: http://www.merck. com/mrkshared/mmanual/section1/chapter1/1b.jsp. Accessed April 11, 2003